Search Demo - PsychoGenics

To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.

Functional Always active

The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.

Preferences

The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.

Statistics

The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.

Marketing

The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.

Filters

Filters

Therapeutic Areas

Specific Disorders

Filters

Elevation of brain magnesium with Swiss chard and buckwheat extracts in an animal model of reduced magnesium dietary intake

Molecular Biomarkers and Disease Markers at PsychoGenics [WEBINAR]

PsychoGenics Chief Innovation Officer Honored for Scientific Excellence

Preclinical Seizure and Epilepsy [WEBINAR]

AI-driven Phenotypic Drug Discovery at PsychoGenics [WEBINAR]

Preclinical Mouse Models of Huntington’s Disease at PsychoGenics [WEBINAR]

Use of Phenotypic Screening in Mice in the Development of a Novel Non-D2-Receptor-Targeting Drug for the Treatment of Schizophrenia

Novel brain permeant mTORC1/2 inhibitors are as efficacious as rapamycin or everolimus in mouse models of acquired partial epilepsy and tuberous sclerosis complex

PsychoGenics Further Strengthens its Leadership Team, Adding Three Senior Executives

Let’s Find the Right Solution Together

Quick Links

Contact

Address

Email

Phone

Fax